MedTech Hiring Strategy Across the Device Lifecycle

The Medical Device Lifecycle Is Predictable – Your Hiring Strategy Should Be Too

One of the most consistent patterns in medical device development is how predictable the stages are. From early concept work through to post-market surveillance, the regulatory gates, clinical milestones, and quality system requirements follow a well-worn path. Yet despite this predictability, talent gaps routinely emerge at the worst possible moments – right before a critical submission, at the start of a V&V programme, or in the run-up to a commercial launch.

This is not a resourcing failure. It is a planning failure. And understanding why requires looking at the financial and regulatory realities that shape each stage of the device development journey – particularly the growing divergence between the US and EMEA environments.

The Cost Context: Why Timing Matters So Much

Medical device development is an expensive undertaking, and the numbers help explain the urgency of getting hiring right first time.

A 2022 analysis published by the US Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation (ASPE) found that the mean direct development cost for a novel complex therapeutic device reached $54 million – and when failures and the cost of capital are factored in, the capitalised mean rises to $522 million. For Class II devices, which represent the majority of devices on the market, total funding requirements of around $30 million are typical.

In Europe, the picture is equally demanding, if differently structured. The EU Medical Device Regulation (EU MDR) has introduced a significantly heavier compliance burden than its predecessor. A European Commission-commissioned evaluation conducted across 2024 and 2025 found that while the MDR has strengthened safety and performance outcomes, it has also produced “high and often disproportionate compliance costs” for manufacturers – driven by regulatory complexity, notified body bottlenecks, expanded clinical evidence requirements, and the demands of post-market clinical follow-up (PMCF).

These costs are not theoretical. They compound with time, and a delayed hire at any major gate can translate directly into delayed revenue – or a failed submission.

What Slowing Down Looks Like in Practice: The EU MDR Example

The EU MDR transition offers a live case study in what happens when resourcing lags behind regulatory demand. As of early 2025, notified bodies had issued only 6,978 MDR certificates against more than 20,000 applications – with review timelines for 40% of applications already stretching to between 13 and 18 months, a figure expected to extend further as transition deadlines approach in 2027 and 2028.

The PA Consulting analysis of this bottleneck makes the underlying dynamic clear: manufacturers that deprioritised compliance resourcing during the extended transition window are now competing for notified body capacity in an increasingly congested queue. In some cases, this has resulted in devices exiting the European market entirely. Over half of manufacturers have reported portfolio reductions as a direct consequence of EU MDR compliance pressures.

The lesson applies well beyond regulatory affairs. Wherever capacity is constrained and demand is high – whether that is notified bodies, V&V engineers, or regulatory submission writers – organisations that move early have a structural advantage.

Aligning Hires to Development Milestones

The logic of lifecycle-aligned hiring is straightforward: the specialisms required at each stage are relatively predictable, and the lead time to bring experienced talent on board should be factored into programme planning from day one.

In the concept and discovery phase, the decisions made by systems engineers, human factors engineers, and early regulatory strategists will constrain or enable everything that follows. These roles are not optional until funding is confirmed – they are the foundation on which the design architecture is built.

As programmes move into prototyping and design control, multidisciplinary engineering teams need to be in place well ahead of formal testing cycles. Verification and validation is among the most documentation-intensive phases in the entire lifecycle, and experienced V&V engineers with FDA or EU MDR familiarity do not arrive ready-made at short notice.

Regulatory resourcing warrants particular attention in EMEA, where a 510(k) or De Novo equivalent does not exist. CE marking under EU MDR requires technical file authors, notified body liaison capability, and clinical evaluation writers with direct MDR experience – a talent pool that remains relatively small. Building that capability 9 to 12 months before a planned submission is not conservative planning; it is standard programme management.

Onto Commercialisation

The commercialisation phase adds another layer of complexity in Europe specifically. A CE mark does not confer market access across all 27 EU member states. Health Technology Assessment (HTA) bodies operate at a national level, each with their own pricing and reimbursement frameworks, and in-country commercial teams need sufficient runway to develop those relationships before a device reaches the market.

Post-market surveillance and vigilance functions are frequently treated as an afterthought – resourced reactively after regulatory approval rather than built in advance. Under both FDA and EU MDR frameworks, PMS is a live obligation from day one of commercial availability. PMCF planning, complaint handling infrastructure, and PRRC oversight in the EU should be operational before a device reaches the market, not assembled in response to it.

The Compounding Effect of Hiring Delays

The financial stakes are well understood at the programme level. A $30 million Class II development programme does not allow much room for avoidable delays. A complex PMA-track device with a capitalised cost in the hundreds of millions tolerates even less.

The cost of a delayed hire is rarely visible on a single line of a project budget. It appears instead in extended timelines, rework, regulatory responses that take longer than planned, and commercial launches that miss their windows. For companies operating across both the US and EMEA simultaneously, the compounding effect of misaligned resourcing in two regulatory environments can be significant.

The medical device lifecycle is, in many respects, one of the most clearly charted development processes in any industry. The milestones are known. The expertise required at each one is documented. The question is whether hiring strategy reflects that knowledge – or whether talent continues to be treated as a reactive response to pressure rather than a proactive element of programme planning.

By Dan Bennett, Client Services Director, Skills Alliance